^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    TIM-3 antagonist

    Related drugs:
    23d
    A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer (clinicaltrials.gov)
    P1/2, N=83, Active, not recruiting, GlaxoSmithKline | Trial completion date: Jan 2032 --> Oct 2026 | Trial primary completion date: Jan 2032 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    Jemperli (dostarlimab-gxly) • cobolimab (TSR-022)
    1m
    A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) (clinicaltrials.gov)
    P1, N=463, Active, not recruiting, Tesaro, Inc. | Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2025 --> Mar 2027
    Enrollment closed • Trial primary completion date
    |
    Opdivo (nivolumab) • cisplatin • carboplatin • docetaxel • pemetrexed • Jemperli (dostarlimab-gxly) • cobolimab (TSR-022) • encelimab (TSR-033)
    2ms
    Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 (clinicaltrials.gov)
    P1, N=60, Completed, Tesaro, Inc. | Active, not recruiting --> Completed | Trial completion date: Aug 2024 --> Dec 2024
    Trial completion • Trial completion date
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • carboplatin • Zejula (niraparib) • albumin-bound paclitaxel • pemetrexed • Jemperli (dostarlimab-gxly) • cobolimab (TSR-022)
    2ms
    MBG453 in Lower Risk MDS (clinicaltrials.gov)
    P2, N=20, Active, not recruiting, Massachusetts General Hospital | Recruiting --> Active, not recruiting | Trial completion date: Jan 2026 --> Nov 2026 | Trial primary completion date: Jun 2024 --> Nov 2024
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Chr del(5q)
    |
    sabatolimab (MBG453)
    2ms
    COSTAR Lung: Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy (clinicaltrials.gov)
    P3, N=758, Active, not recruiting, GlaxoSmithKline | Trial completion date: Oct 2025 --> Mar 2027
    Trial completion date
    |
    docetaxel • Jemperli (dostarlimab-gxly) • cobolimab (TSR-022)
    3ms
    Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM (clinicaltrials.gov)
    P1, N=16, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Sep 2025 --> Sep 2026
    Trial completion date
    |
    MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    spartalizumab (PDR001) • sabatolimab (MBG453)
    4ms
    Elevated TIM3 expression on bone marrow T cells drives immune dysfunction in early relapsed blood cancer after allogeneic hematopoietic stem cell transplantation. (PubMed, Exp Hematol Oncol)
    Functional assays demonstrated that TIM3 blockade with sabatolimab restored T cell cytotoxicity, leading to enhanced leukemia cell apoptosis in ER patients. These findings highlight TIM3 as a critical regulator of T cell exhaustion and immune suppression in patients with ER and provide a rationale for the therapeutic use of TIM3 blockade in preventing and treating relapses after allo-HSCT.
    Journal
    |
    ER (Estrogen receptor) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2)
    |
    sabatolimab (MBG453)
    4ms
    A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer (clinicaltrials.gov)
    P1/2, N=95, Active, not recruiting, GlaxoSmithKline | Trial primary completion date: Oct 2029 --> Jan 2032 | Recruiting --> Active, not recruiting
    Enrollment closed • Trial primary completion date
    |
    Jemperli (dostarlimab-gxly) • cobolimab (TSR-022)
    4ms
    STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS (clinicaltrials.gov)
    P2, N=39, Terminated, Novartis Pharmaceuticals | Completed --> Terminated; Lack of efficacy in the program as demonstrated in the earlier CMBG453B12301 (STIMULUS MDS-2) study.
    Trial termination
    |
    azacitidine • decitabine • Inqovi (decitabine/cedazuridine) • sabatolimab (MBG453)
    5ms
    Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer: AMBER Part 2B. (PubMed, Clin Cancer Res)
    Cobolimab plus dostarlimab showed preliminary efficacy and tolerability in a subset of patients with locally advanced/metastatic NSCLC. See related article by Davar et al., p. XX.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2)
    |
    Jemperli (dostarlimab-gxly) • cobolimab (TSR-022)
    5ms
    Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2A. (PubMed, Clin Cancer Res)
    In this exploratory setting, cobolimab plus dostarlimab was well tolerated, with reported preliminary efficacy similar to other anti-T-cell immunoglobulin and mucin-domain containing protein-3 treatments in patients with locally advanced/metastatic melanoma. See related article by Davar et al., p. XX.
    Journal
    |
    PD-1 (Programmed cell death 1) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2)
    |
    Jemperli (dostarlimab-gxly) • cobolimab (TSR-022)
    6ms
    STIMULUS-AML2: Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation. (clinicaltrials.gov)
    P1/2, N=24, Terminated, Novartis Pharmaceuticals | Completed --> Terminated; Study was stopped following a strategic decision from the Sponsor. It was not based on any safety findings or safety concerns with sabatolimab.
    Trial termination
    |
    azacitidine • sabatolimab (MBG453)